It's clear that there are multiple trials to consider in the name of brain cancer, some of them more recognized than others. However, it's clear that most of them are done over an extended stretch of time, seeing as how details are going to have to be picked up on. I feel as though this is for the best, seeing as how you can't exactly learn much over a day's time. This is especially true when considering the lengthy nature of study of the ETS2101 drug.
For those who do not know what the ETS2101 trial is, it entails a series of patients who have both primary and secondary brain cancer. According to an article on the Wall Street Journal, this procedure has been put into place for the sake of witnessing whether ETS2101 is safe for helping this condition or not. A certain dose has been applied and results have been surveyed to see if said dose is safe in addition to beneficial. The trial will continue on through 2014, which is something that organizations like Voices against Brain Cancer should make note of.
Of course, you may stop and wonder what exactly ETS2101 is. The article spoke about it and it's been said that it a drug commonly utilized in order to treat patients with trauma. Thanks to pharmacology, though, it's been believed that this drug can actually prove useful for the sake of helping cancer patients, too. Two studies are being done, one with primary cancer patients and the other entailing secondary cancer patients. To say that there has been quite a bit of time invested here would be an understatement.
With this procedure put into place, though, it's been said that patients have been given steadily higher doses over time until a tolerated level has been reached. Fifteen different patients have completed the studies and they were all given appropriate levels of the drug relative to body weight. The results have been positive, from what I have picked up on, as the tumors did not respond negatively to the drug. It's this level of success that, in my mind, can lead to further results down the road.
It's clear that studies of this nature require time in order for them to be as effective as possible. Brain cancer, as one can imagine, is a serious condition and it deserves to be focused on consistently. The story regarding the usage of the ETS2101 drug is a strong one and it seems as though there have been results which can come into play later on. My only hope is that there are greater results which can then become even greater as more time - in addition to attention - is given.
For those who do not know what the ETS2101 trial is, it entails a series of patients who have both primary and secondary brain cancer. According to an article on the Wall Street Journal, this procedure has been put into place for the sake of witnessing whether ETS2101 is safe for helping this condition or not. A certain dose has been applied and results have been surveyed to see if said dose is safe in addition to beneficial. The trial will continue on through 2014, which is something that organizations like Voices against Brain Cancer should make note of.
Of course, you may stop and wonder what exactly ETS2101 is. The article spoke about it and it's been said that it a drug commonly utilized in order to treat patients with trauma. Thanks to pharmacology, though, it's been believed that this drug can actually prove useful for the sake of helping cancer patients, too. Two studies are being done, one with primary cancer patients and the other entailing secondary cancer patients. To say that there has been quite a bit of time invested here would be an understatement.
With this procedure put into place, though, it's been said that patients have been given steadily higher doses over time until a tolerated level has been reached. Fifteen different patients have completed the studies and they were all given appropriate levels of the drug relative to body weight. The results have been positive, from what I have picked up on, as the tumors did not respond negatively to the drug. It's this level of success that, in my mind, can lead to further results down the road.
It's clear that studies of this nature require time in order for them to be as effective as possible. Brain cancer, as one can imagine, is a serious condition and it deserves to be focused on consistently. The story regarding the usage of the ETS2101 drug is a strong one and it seems as though there have been results which can come into play later on. My only hope is that there are greater results which can then become even greater as more time - in addition to attention - is given.
About the Author:
Visit Voices Against Brain Cancer if you're seeking some more information about glioblastoma and brain cancer awareness.. Also published at ETS2101 & Its Value To Brain Cancer.
0 commentaires:
Post a Comment
Thanks for your comment.